Clinical Trial Update: A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP [Phase 3]

View source ↗

Summary

Phase 3 randomized trial comparing low-dose bevacizumab versus laser therapy for Type 1 retinopathy of prematurity was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinopathy of Prematurity

Drugs mentioned

• Bevacizumab (bevacizumab)
• Laser therapy

Snippet

Sponsor: Jaeb Center for Health Research | Conditions: Retinopathy of Prematurity | Phase 3 | Status: TERMINATED | Results posted: 2024-08-01